Abstract
Twenty five years after the structure elucidation of slow reacting substance of anaphylaxis, antileukotrienes are established as a new therapeutic modality in asthma. The chapter reviews the biochemistry and pharmacology of leukotrienes and antileukotrienes with particular focus on the different usage of antileukotrienes for treatment of asthma and rhinitis in Europe and the US. Further research needs and new areas for leukotriene involvement in respiratory diseases are also discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acetates / pharmacology
-
Acetates / therapeutic use
-
Animals
-
Asthma / drug therapy*
-
Asthma / metabolism
-
Clinical Trials as Topic
-
Cyclopropanes
-
Humans
-
Hydroxyurea / analogs & derivatives
-
Hydroxyurea / pharmacology
-
Hydroxyurea / therapeutic use
-
Leukotriene Antagonists / pharmacology
-
Leukotriene Antagonists / therapeutic use*
-
Leukotriene C4 / antagonists & inhibitors
-
Leukotriene C4 / metabolism
-
Leukotriene D4 / antagonists & inhibitors
-
Leukotriene D4 / metabolism
-
Leukotriene E4 / antagonists & inhibitors
-
Leukotriene E4 / metabolism
-
Lipoxygenase Inhibitors / pharmacology
-
Lipoxygenase Inhibitors / therapeutic use*
-
Membrane Proteins / antagonists & inhibitors
-
Membrane Proteins / metabolism
-
Quinolines / pharmacology
-
Quinolines / therapeutic use
-
Receptors, Leukotriene / metabolism
-
Respiratory System / drug effects
-
Respiratory System / metabolism
-
Rhinitis / drug therapy
-
Rhinitis / metabolism
-
Sulfides
Substances
-
Acetates
-
Cyclopropanes
-
Leukotriene Antagonists
-
Lipoxygenase Inhibitors
-
Membrane Proteins
-
Quinolines
-
Receptors, Leukotriene
-
Sulfides
-
Leukotriene C4
-
Leukotriene D4
-
Leukotriene E4
-
leukotriene D4 receptor
-
montelukast
-
zileuton
-
Hydroxyurea